Fatty Liver, Nonalcoholic Clinical Trial
Official title:
Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy
Verified date | September 2021 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-alcoholic fatty liver disease is excessive fat build-up in the liver with insulin resistance due to causes other than alcohol use.The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease.Currently, the only treatment modality for patients with fatty liver disease is weight loss and exercise which is challenging for most patients. Therefore, a huge need exists for an alternative approach to reducing alanine transaminase (ALT) & aspartate aminotransferase (AST) levels for these patients. Low level laser light therapy (LLLT) offers a simple, non-invasive, safe, effective and side-effect free alternative to achieving this goal, through LLLT's proven ability to effect weight loss, body circumference reduction and lipid profile modification
Status | Completed |
Enrollment | 60 |
Est. completion date | September 1, 2021 |
Est. primary completion date | July 25, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 75 Years |
Eligibility | Inclusion Criteria: - • Sixty non-alcoholic fatty liver patients aged from 60-75 y - Body mass index (BMI) ranged from 30 to 34.9 kg/m2 - Elevated triglyceride & LDL levels - Higher Risk Waist Circumference Measurements (Men: 40 or more inches or 102 centimeters or more/ Women: 35 or more inches or 89 centimeters or more) - Elevated aminoalanine transaminase (ALT) level, defined as 20 or more Unites/Liter (U/L) above the normal gender-specific ALT levels: males: ALT = 60 U/L; females: ALT = 50 U/L - Review of subject's pre-existing medical records to confirm the current diagnosis of nonalcoholic fatty liver according to the following criteria: - ALT elevated on two separate determinations - Abdominal ultrasound showing fatty liver - Blood work that excludes other potential etiologies of liver disease - Subject agrees to maintain his or her diet regimen throughout study participation Exclusion Criteria: - • History of cardiovascular disease or events including, but not limited to, coronary artery disease, valvular heart disease, cardiac arrhythmias, congestive heart failure, myocardial infarction, stroke, transient ischemic attack, or peripheral vascular disease - Cardiac surgeries or procedures, including but not limited to, coronary artery bypass surgery or stent placement, heart transplantation, pacemaker insertion or implantation of a defibrillator - An implanted device in the target area to receive low level laser light therapy (e.g. pain pump, lap band, penile inflation device, ventriculo-peritoneal shunts, etc.) - Known photosensitivity disorder - Current active cancer or within one year of cancer treatment or remission - Excessive alcohol consumption defined as 14 or more alcoholic drinks per week - Serious mental health illness that in the opinion of the investigator would preclude the subject from study participation - Active infection, wound or other external trauma to the target area to receive the laser therapy - Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements - Participation in a clinical study or other type of research in the past 30 days |
Country | Name | City | State |
---|---|---|---|
Egypt | Cairo | Giza | Dokki |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | changes in liver function | measuring liver enzymes (alanine transaminase (ALT) & aspartate aminotransferase (AST) ) and alkaline phosphate before and after low level laser application and the prescribed diet recommendations | 3 months | |
Secondary | changes of lipid profile | measuring effect of low level laser application in addition to diet recommendations on lipid profile (low density lipoprotein LDL, high density lipoprotein HDL, total cholesterol T.C and triglyceride T.G) | 3 months | |
Secondary | changes of Body Mass Index | measuring effect of low level laser application in addition to diet recommendations on body mass index (weight by Kg / height per meter square) | 3 months | |
Secondary | changes of waist circumference | measuring effect of low level laser application in addition to diet recommendations on waist circumference | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03319199 -
The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
|
N/A | |
Recruiting |
NCT05220956 -
Impact of Time-restricted Feeding in NAFLD
|
N/A | |
Active, not recruiting |
NCT04067440 -
Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
|
||
Completed |
NCT04509245 -
The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes
|
N/A | |
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Not yet recruiting |
NCT06117137 -
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT02132780 -
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
|
N/A | |
Active, not recruiting |
NCT04241575 -
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
|
N/A | |
Completed |
NCT02290106 -
Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
|
N/A | |
Completed |
NCT03784716 -
Ketogenic Diet in Non-alcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT05558592 -
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
|
N/A | |
Active, not recruiting |
NCT06445335 -
Prevalence of NAFLD in T2DM Patients
|
N/A | |
Active, not recruiting |
NCT05855239 -
Quantification of Hepatic Steatosis With Different Ultrasound Frequency
|
||
Recruiting |
NCT05877547 -
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
|
Phase 2 | |
Completed |
NCT04462562 -
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
|
N/A | |
Completed |
NCT04054297 -
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat
|
N/A | |
Completed |
NCT03260543 -
Efficacy and Safety of Fermented Ginseng Powder on Liver Function
|
N/A | |
Not yet recruiting |
NCT06215131 -
Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease
|
N/A | |
Completed |
NCT03593343 -
Hepatic Glycogen and Fat Oxidation
|
N/A | |
Recruiting |
NCT06257732 -
Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines
|
N/A |